- Veterinarian Survey 2020
- What is compounding?
- Facts About FDA's Guidance for Industry #256
- Why Compounding Pharmacies Use Bulk Active Pharmaceutical Ingredients
- Why Compounding from Finished Goods Will Increase Costs
- The Case for Office Use of Compounded Medications
- Anticipatory Compounding: An Important Part of Pharmacy Practice
- Pharmacy or Manufacturer? Size Doesn't Matter.
- The Negatives About FDA’s “Positive List.”
- The Law
ALEXANDRIA, Va. (June 21, 2017) National Community Pharmacists Association (NCPA) CEO B. Douglas Hoey, RPh, MBA, issued the following statement today in support of new compounding legislation, H.R. 2871, The Preserving Patient Access to Compounded Medications Act of 2017, introduced by Reps. Morgan Griffith (R-Va.) and Henry Cuellar (D-Texas), that will improve patient access to compounded medications:
WASHINGTON – June 13, 2017 - The International Academy of Compounding Pharmacists (IACP) strongly supports new legislation, introduced by U.S. Congressmen Morgan Griffith (VA) and Henry Cuellar (TX), HR 2871 – The Preserving Patient Access to Compounded Medications Act of 2017, formally introduced on June 12, 2017. More than 300 compounding pharmacists traveled to Washington, D.C. on behalf of their patients and physicians to meet with their respective congressional representatives to discuss the Bill’s content, and to urge them to co-sponsor HR 2871.
Comments to the Draft Guidance for Industry #230: Compounding Animal Drugs from Bulk Substances
The FDA has granted a 90-day extension to the public comment period on its highly controversial draft guidance for industry (GFI #230) entitled “Compounding Animal Drugs from Bulk Substances” in response to several requests to do so. The comment period will now close on November 16, 2015. Public comments are encouraged at Regulations.gov.